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A B S T R A C T
In the management of large number of patients with differentiated thyroid cancer, the radioactive iodine (131-I) ad-
ministration plays an important role. The guidelines of numerous international and national medical societies regard-
ing the issue of postoperative 131-I administration have been published and updated in the last few years. The guidelines
differ in the shape and content, and contain some specific features. The different methods for evaluation and analysis of
clinical evidence level and resulting grades of recommendations have been used in line with the very guidelines. The
postoperative 131-I administration refers to the radioiodine ablation as a form of adjuvant treatment and radioiodine
therapy in the management of patients with recurrent cancer, persistent disease and regional or distant metastases. Ac-
cording to the indications for the postoperative 131-I administration, the patients could be divided into the three risk
groups: the very low risk group in which there is no indication for the postoperative131-I administration, the low risk
group in which the indication could be considered, and the high risk group in which there is a clear indication for
the131-I administration. The different criteria for distribution of patients into these three groups are expressed in a cer-
tain guidelines. There are different opinions about the necessary dosage of 131-I for the efficient ablation in the low risk
group. Moreover, the opinions are also divided regarding the conduction of postoperative (preablative or pretherapeutic)
scintigraphy with 131-I. As regards the instructions on preparation of patients for the radioiodine ablation and therapy,
all the guidelines recommend the low iodine diet and endogenous or exogenous stimulation of TSH. The endogenous
stimulation is accomplished by the withdrawal of thyroid hormones, whereas the recombinant human TSH (rhTSH) is
used for exogenous stimulation. For conducting the therapy with 131-I the level of TSH has to be >25–30 mU/L.
Key words: differentiated thyroid cancer, thyroid remnant ablation, radioiodine therapy, guidelines, recombinant
human thyrotropin
Introduction
The thyroid cancer is subject of interest to many in-
ternational and national medical societies that are for-
med out by experts of different clinical specialties. In the
last few years the most of societies have published and
updated their recommendations (in the form of guide-
lines; algorithms) regarding the management of patients
with differentiated thyroid cancer (DTC)1–12. The major-
ity of these recommendations (guidelines) are based on
the methods for evaluation of evidence, evaluation and
treatment of thyroid nodules, diagnostics, staging of dis-
ease, initial treatment and follow-up of patients with
DTC. On the grounds that the appliance of the radioac-
tive iodine plays an important role in the treatment of a
large number of patients with DTC, this article presents
the review of recent guidelines that refer to postopera-
tive radioactive iodine (131-I) administration.
This article presents the differences between the gui-
delines regarding the indications and procedures in cases
the postoperative 131-I is applied, characteristics (spe-
cific features) of certain guidelines, the strength of evi-
dence and the grades of recommendations pursuant to
different guidelines. The terms that closely describe the
postoperative use of 131-I have been defined, and the rec-
ommendations regarding the procedures which are to be
conducted prior to radioiodine remnant ablation and
radioiodine therapy have been analyzed. The Table 1
shows the different society guidelines that contain differ-
ent recommendations for various aspects of DTC, that is,
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for the postoperative 131-I administration. All the guide-
lines are recently published in renowned international
journals and are easily available.
The Structure and Characteristics
(Specific Features) of Certain Guidelines
The guidelines, although similar in structure, differ
in their shape and content and have certain specific char-
acteristics (features). The guidelines of the American
Thyroid Association (ATA) are presented in the form of
questions and answers. The answers are given in a form
of short discussion with references from the respective
literature and the recommendations (together with the
level of evidence)3. The guidelines of the American Asso-
ciation of the Clinical Endocrinology, which are issued in
cooperation with the Italian Associazione for Medici En-
docrinologi (AACE/AME), provide us with the detailed
recommendations for management of patients with thy-
roid nodules, but they lack the part that refers to the use
of the radioiodine therapy2. On the other hand, the use of
the radioiodine therapy represents the main part of the
European Association of Nuclear Medicine guidelines
(EANM)8 and the Consensus report about postsurgical
use of radioiodine and the issue of remnant ablation
(ETA/ABL)10.
The most extensive guidelines are the ones of the
Dutch Endocrine Society and Society of Nuclear Medi-
cine (Dutch), that on more than 150 pages give recom-
mendations that are based on 599 references7. The gui-
delines that are mutually brought by the British Thyroid
Association and the Royall College of Physicians (BTA)
contain the detailed instructions for the general practi-
tioners as well as for the patients who are important par-
ticipants in the management of DTC. The guidelines are
updated every five years (working version of 2002, cur-
rent version of 2007, which is planned to be revised in
the course of the year 2012)4. The National Comprehen-
sive Cancer Network (NCCN; USA) presents the guide-
lines in the form of algorithms, decision pathways and
practical clinical guidelines, respectively. The algorithms
are followed by the text and the references that contain
the discussion about the aspects related to the algorithm.
The guidelines are updated on a regular basis, therefore
the current version dates from the year 2011 (the previ-
ous version is from 2010)12.
A part of the EANM guidelines describes in detail the
dosimetry of the tumor and the dosimetry of the bone
marrow. Also, it gives detailed description of the proce-
dures as well as the early and late effects of the radioio-
dine therapy8. The European Consensus for the Manage-
ment of Patients with Differentiated Thyroid Carcinoma
of the Follicular Epithelium (ETA) is adopted in a form of
joint statement of the European Thyroid Association
experts9. The above mentioned ETA/ABL consensus has
already been established by the experts of ETA10. The
European Society for Medical Oncology guidelines
(ESMO) are based on ETA and ATA guidelines11. Joined
guidelines of German Endocrine and Nuclear Medicine
Society (DGN) consist of three separate documents: Pro-
cedure guidelines for the radioiodine therapy of DTC, the
guidelines for the 131-I whole body scintigraphy and the
guidelines for the pediatric patients with DTC6. The
backbone of the Croatian guidelines for the treatment of
patient with DTC (CTS) is made of the four detailed algo-
rithms; two of them refer to the diagnostics and the
other two on the DTC therapy5 (Figure 1).
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TABLE 1
DIFFERENT SOCIETY GUIDELINES FOR THE TREATMENT OF DIFFERENTIATED THYROID CANCER
AACE/AME (American Association of Clinical Endocrinologists and Italian Associazione for Medici Endocrinologi):2006; Medical
guidelines for clinical practice for the diagnosis and management of thyroid nodules
ATA (American Thyroid Association): 2009; Revised American Thyroid Association Management Guidelines for Patients with
Thyroid Nodules and Differentiated Thyroid Cancer
BTA/RCP (British Thyroid Association and Royal College of Physicians): 2007; Guidelines for management of thyroid cancer
Croatian Thyroid Society: 2008; Guidelines for the management of patients with differentiated thyroid cancer
DGE/DGN (German Endocrine and Nuclear Medicine Society): 2007; Procedure guidelines for radioiodine therapy of differentiated
thyroid cancer (version 3)
Dutch Endocrine Society and Society of Nuclear Medicine: 2007; Nationwide guideline thyroid carcinoma
EANM (European Association of Nuclear Medicine):2008; Guidelines for radio-iodine therapy of differentiated thyroid cancer
ETA (European Thyroid Association): 2006; European consensus for the management of patients with differentiated thyroid
carcinoma of the follicular epithelium
ETA (European Thyroid Association):2005; Post-surgical use of radio-iodine (I-131) in patients with papillary and follicular
thyroid cancer and the issue of remnant ablation: a consensus report
ESMO (European Society for Medical Oncology): 2010; Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up
NCCN (National Comprehensive Cancer Network): 2011; Version. 1; Practice guidelines in oncology – Thyroid Carcinoma
The Level of Clinical Evidence and
Grading of Recommendations Used in
the Guidelines
Different methods of evaluation and analysis of the
strength of scientific evidence are used in the guideli-
nes13. All the listed guidelines are created by expert pro-
fessional bodies, and in some of the guidelines evidence is
evaluated according to strength (Table 2). The ATA gui-
delines divide the recommendations into seven grades
depending on the level of evidence3,14. In the NCCN
guidelines there are four categories of recommendations.
All recommendations are category 2A unless otherwise
noted12. The BTA guidelines, according to the type of evi-
dence, define six levels of evidence and three grades of
recommendation4. The Dutch guidelines differ the levels
of evidence for the procedures that apply to the interven-
tion or the diagnosis. Resulting level of evidence for rec-
ommendation is divided in four categories (1, 2, 3 and 4)7.
The authors of the EANM guidelines, instead of formally
categorizing the level of evidence due to low-level strength
of evidence in many aspects of treatment, diagnostic and
follow-up of the patients with DTC, have listed the refer-
ences of the significant trials through which they argu-
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Fig. 1. Example of algorithm: primary treatment of differentiated thyroid carcinoma (Algorithm of treatment and follow up by Croatian
Throid Society; Reproduced with permission; Copyright © 2007 Croatian Thyroid Society. All Rights Reserved5).
Abbrevations: L-T4 – levothyroxine; TSH- thyrostimulating hormone, rhTSH – recombinant human TSH, neck US – ultrasound of the
cervical region; WBS – whole body scintigraphy; Tg – thyroglobulin; TgA – antithyroglobulin antibodies.
TABLE 2
STRENGTH OF RECOMMENDATIONS BASED ON THE AVAILABLE EVIDENCE USED IN VARIOUS GUIDELINES
ATA NCCN Brits* Dutch**
The recommendation is based
on high level of evidence (e.g.
meta analysis; randomized
control trials)
A – strongly recommends
F – strongly recommends
against
Category 1 A (la, lb) A1A2
The recommendation is based




E – recommends against Category 2A B (IIa, IIb, III)
B
C
Evidence obtained from expert
committee reports or opinions
C – recommends
D – recommends against Category 2B C (IV) D
Disagreement among experts/
Insufficient evidence




* Types of evidence that the grades of recommendation are based on, are presented in the brackets
** For procedures regarding intervention and for procedures regarding diagnosis
ment their recommendations8. Some other guidelines are
also based on the quotations of the »significant« trials
and on the »evidence based« medicine, but do not indi-
cate the strength of clinical evidence and grades of re-
commendations5,6,9,10.
The Postoperative Radioactive Iodine
Administration: Definition
In the postoperative 131-I administration, the terms
radioiodine ablation and radioiodine therapy can differ.
Certain societies use the term radioiodine ablation for
the postoperative 131-I administration in all patients,
like ATA, which defines the term radioiodine ablation as
the postoperative 131-I administration in patients of all
risk groups with appropriate indication3. The ETA also
considers the postoperative 131-I administration in two
risk groups with appropriate indication9 as radioiodine
ablation. The authors of Dutch guidelines define the
term ablation in the postoperative 131-I administration
by using different activities7. The ESMO also states the
term ablation of the thyroid remnant, in the low and
high risk groups11. In the CTS guidelines all terms that
refer to the postoperative 131-I administration use the
term ablation independently of the risk group5.
Authors of certain guidelines differentiate radioiodi-
ne ablation as a form of adjuvant appliance of the 131-I,
whereas radioiodine therapy stands for the appliance of
the 131-I in the high risk group of patients. The DGN
guidelines differentiate radioiodine therapy used for the
adjuvant thyroid remnant ablation from radioiodine the-
rapy in patients with local recurrence, positive lymph
nodes and distant metastases6. The NCCN guidelines
also differentiate adjuvant radioiodine ablation of the
thyroid bed with lower activities from radioiodine ther-
apy with higher activities12. According to the BTA guide-
lines radioiodine ablation refers to the 131-I induced de-
struction of the thyroid remnant, whereas the term
radioiodine therapy refers to the 131-I administration in
treating loco-regional recurrence or metastatic disease4.
In the EANM guidelines the administration of 131-I
stands for the ablation as a post-surgical adjuvant modal-
ity and for the treatment of unresectable or incompletely
resectable lesions8.
Indications for the Postoperative
Radioactive Iodine Administration
Indication for the administration of the postoperative
radioiodine ablation (therapy) is often considered in some
guidelines. Most of the guidelines use the UICC-AJCC-
-TNM classification to divide the patients into different
risk groups15. Depending on the indication, patients can
be divided into three groups; a group where there is no
indication for the 131-I administration, a group where
the administration of the 131-I could be considered and a
group where there is a clear indication for the 131-I ad-
ministration. There are some differences in the defini-
tion of the group of patients with DTC where there is no
indication for the postoperative administration of the
131-I. It is considered that administration of iodine in
this group is not indicated due to low risk of recurrence
or mortality.
ETA defines this group as one of very low risk, and it
includes the patients with complete surgery, favorable
histology, unifocal with tumor size 1 cm, N0, M0 and
without extrathyroid extension9. Dutch guidelines rec-
ommend unilateral lobectomy for the unifocal papillary
carcinomas smaller than <1 cm without positive lymph
node or distant metastases, while the 131-I administra-
tion is not indicated7. The BTA also considers lobectomy
as a sufficient surgical procedure in the group of patients
with complete surgery, favorable histology, unifocal tu-
mor 1 cm in diameter, N0, M0, or minimally invasive
follicular thyroid carcinoma, without vascular invasion,
smaller than 2 cm in diameter and without extension be-
yond the thyroid capsule4. The DGN guidelines include
patients with papillary microcarcinoma (size 1 cm) in
this group where total or near-total thyroidecomy isn’t
mandatory6. According to the NCCN guidelines there is
no indication for radioiodine therapy in patients with
limited tumor size (<1 cm), favorable histology, with no
local or distant metastasis, thyroglobulin (Tg) level <1
ng/mL with negative antithyroglobulin antibodies (TgA),
and negative whole body scintigraphy12.
The ATA also doesn’t recommend radioiodine abla-
tion in patients with solitary and multifocal tumors
where all foci are smaller than 1 cm, but with no other
high risk features. However, the strength of this recom-
mendation is low, and is based on expert opinion3. Ac-
cording to the EANM guidelines radioiodine therapy is
not necessary in patients with unifocal papillary carci-
noma with 1 cm in diameter, without metastasis, thy-
roid capsule invasion, previous radiation exposure and
unfavorable histology8. The CTS in the group of very low
risk includes the patients with complete surgery, unifocal
tumor 1 cm, N0, M0, with no thyroid capsule penetra-
tion and with favorable histology5.
Ablation in the Low-risk Group of Patients
The radioiodine ablation in the low-risk group of pa-
tients is the subject of many debates. The ablation bene-
fit is not yet confirmed with clear evidence16–18. Also,
there are different opinions about the optimal activities
of the 131-I required for effective ablation of the thyroid
residue in this group of patients19–22. The ETA introduces
probable indication in patients younger than 18 years
with tumor T>1 cm; in case of less than total thyroidec-
tomy or no lymph node dissection, with T2, N0, M0 or in
case of unfavorable histology, meaning that in some pa-
tients from this group the radioiodine administration
could be avoided. In the case of application it is advised to
use 30 mCi or 100 mCi of 131-I9. The ETA/ABL consen-
sus has identical criteria with the difference that pa-
tients younger than 16 years are included in this group10.
The ATA recommends radioiodine ablation in patients
with tumor size from 1 to 4 cm, lymph node metastases
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and other features which increase the risk of recurrence
or death with activities from 30–100 mCi3. The ESMO
guidelines quote ATA and ETA guidelines in the post-
ablative staging and in the risk evaluation11.
The probable indication, according to the BTA/RCP
guidelines, includes patients with less than total thyroi-
dectomy where status of lymph nodes is not assessed at
surgery, with tumor size between >1 cm and <4 cm in di-
ameter, tumors <1 cm in diameter with unfavorable his-
tology and multifocal tumors. In the version from the
year 2002, it is advised to use 30–100 mCi, however in
the version from the year 2007 the recommendations are
for the usage of higher activities (100 mCi) of the 131-I4.
The Dutch recommend the activities of 50–100 mCi for
the thyroid remnant ablation after the thyroidectomy.
The ablation is recommended in all patients with DTC,
except in those without indications (above mentioned)7.
In the DGN guidelines the radioiodine ablation is consid-
ered as a standard procedure. In microcarcinomas the
administration of the radioiodine therapy could be con-
sidered depending on the prognostic factors such as
closeness to the capsule, family history, previous neck ra-
diation, 5–10 mm tumor diameter. In case of application,
the activities from 54 to 100 mCi of 131-I are recommen-
ded6.
The NCCN indicates the radioiodine ablation where,
accordingly to the clinical data and 131-I whole body
scintigraphy, there exists a reasonable doubt (based on
pathology, postoperative values of Tg and on intraope-
rative findings) or if the thyroid bed uptake is proven.
The recommended activities are 30–100 mCi12. The EANM
considers radioiodine ablation after the total or near to-
tal thyroidectomy as a standard procedure in the pa-
tients with DTC (except above mentioned). They discuss
about the activities in the range from 1 to 5 GBq (27–135
mCi), but no clear recommendations on optimal 131-I
dosage are given8. The CTS guidelines include in this
group all patients that do not belong in the very low risk,
or in the high risk group. In this group of patients (T1>1
cm, T2, N0, M0 and T1 multifocal) the application of low
and high activities of 131-I is indicated5.
Radioiodine Therapy in the High-risk
Group of Patients
In the postoperative treatment of the high risk pa-
tients, the authors of the guidelines agree that there is a
definite indication for the radioiodine therapy adminis-
tration, and suggest the use of higher therapeutic activi-
ties of 131-I. The ETA includes in this group patients
with persistent disease or with high risk of persistent or
recurrent disease, which includes patients with distant
metastases or incomplete tumor resection or with com-
plete tumor resection, but high risk for recurrence or
mortality, tumor extension beyond the thyroid capsule
(T3 or T4) or lymph node involvement. In this group the
recommended postoperative 131-I activities are higher
than 100 mCi9. Similarly to the the ETA guidelines, BTA
guidelines also have definite indication for the 131-I ad-
ministration in case of patient with distant metastases,
incomplete tumor resection, but high risk for recurrence
or mortality4.
The ATA guidelines include radioiodine therapy in all
patients with distant metastases and extra-thyroid inva-
sion regardless of tumor size and tumors larger than 4
cm3. According to the DGN guidelines this group in-
cludes the patients with local recurrence, lymph nodes
metastases and distant metastases. The use of high activ-
ities of 131-I (up to 200 mCi) is recommended6. The au-
thors of the NCCN guidelines recommend the adminis-
tration of high 131-I activities (100–200 mCi) in case of
doubt (based on pathology, postoperative Tg values and
intraoperative findings) or proven tumor remnant up-
take of 131-I12. The EANM recommends multiple admin-
istrations of 100–200 mCi 131-I in patients with unre-
sectable or partially resectable tumor (for example, local
recurrence, lymph nodes metastases or disseminated lung
metastases or any other distant iodine-avid metastases)8.
The CTS guidelines in the high risk group include pa-
tients with incomplete tumor resection, distant or re-
gional metastases (N1, M1), extrathyroidal extension
(T3, T4) and with unfavorable histology. The authors
suggest the administration of 131-I activities in the ran-
ge of 100 to 200 mCi5,23. In the Dutch guidelines for the
patients with positive lymph nodes and distant meta-
stases diagnosed with postoperative scintigraphy as for
the patients that haven’t undergone through the radical
resection of the primary tumor, the recommended 131-I
activities are in the rage from 100 to 200 mCi7.
The Preparations for Radioiodine Ablation
and Therapy
TSH level
Preparation of patients for the postoperative 131-I
administration includes a certain procedures that apply.
The authors of the guidelines agree that certain level of
the thyrostimulating hormone (TSH) in the serum needs
to be reached. The needed level of TSH is slightly differ-
ent depending on the guidelines: TSH>25 mU/L7 TSH>
25–30 mU/L10; TSH30 mU/L8; TSH>30 mU/L3–6,9. This
TSH level can be accomplished endogenously (by thyroid
hormone withdrawal or pausing with thyroid hormone
intake) or exogenously (by using recombinant human
TSH – rhTSH)24–27.
Preparation of adequate TSH stimulation
The ATA guidelines recommend withdrawal of the
levothyroxine (L-T4) for at least 2–3 three weeks in the
preparation of the patient for the ablation. Also, 131-I
ablation can be performed following rhTSH stimulation,
which was approved in the USA for remnant ablation in
year 20073,28. The NCCN recommends the administra-
tion of 131-I in the period from 2 to 12 weeks after the
thyroidectomy and the use of both methods of TSH stim-
ulation (the thyroid hormone withdrawal or stimulation
with rhTSH)12. In the ETA guidelines the withdrawal of
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the L-T4 is recommended during 4–5 weeks9. The use of
rhTSH is approved in Europe in low risk patients for the
administration of 100 mCi 131-I29.
The Dutch consider the thyroid hormone withdrawal
as a »gold standard« procedure, and as an alternative,
the rhTSH can be used in the low risk patients for activi-
ties of 100 mCi7. Unlike the Dutch guidelines, the EANM
gives the advantage to the rhTSH (if it is economically
justified) as a method of TSH stimulation in moderate or
high ablation activities (50–100 mCi 131-I) and in pa-
tients which are unable to tolerate the symptoms of
hypothyroidism or in which the acceptable level of the
TSH couldn’t be reached endogenously. The endogenous
rise of the TSH is accomplished by not administering
L-T4 replacement therapy for at least 3 weeks after the
thyroidectomy in recently operated patients or for 4–5
weeks after the withdrawal of the LT4 in patients on
L-T4 replacement therapy. For the ablation with the
smaller activities both methods of preparation are rec-
ommended, while the endogenous stimulation has the
advantage when treating the metastatic disease8. The
authors of the DGN guidelines recommend the radio-
iodine therapy 3–5 weeks after the thyroidectomy or 4–5
weeks after the withdrawal of the LT4. After stimulation
with the rhTSH, high ablation effectiveness can be no-
ted6.
For the rise of TSH according to the CTS guidelines
the recommendation is the withdrawal of L-T4 suppres-
sion therapy during four weeks or performing 131-I ad-
ministration 4 weeks after the thyroidectomy. The use of
rhTSH is approved in 2007 for the ablation of thyroid tis-
sue in low risk patients with 100 mCi 131-I. The rhTSH
can be used in metastatic disease when the endogenous
rise of serum TSH is insufficient, when prolonged L-T4
withdrawal is contraindicated, when the withdrawal is
poorly tolerated or when the delay in therapy might be
deleterious5. In the BTA guidelines the period of 3–4
weeks after the thyroidectomy and without the L-T4 is
considered to be enough time for the rise of TSH on satis-
fying level4. In the endogenous method of stimulation,
especially when there is longer period between the opera-
tion and planned ablation, as an alternative to the L-T4
withdrawal, many guidelines state the use of triiodothy-
ronine (L-T3) and its withdrawal two weeks before the
planned administration of 131-I3–6,8,9.
A low iodine diet
A low iodine diet is used during the preparation of pa-
tients for radioiodine ablation/therapy and it is indis-
pensable part in the most of guidelines. This diet is espe-
cially recommended to patients with high iodine intake.
The most extensive instructions about the low iodine
diet and the groceries that should be avoided are listed in
the Dutch guidelines. Its implementation is recommen-
ded in patients with low thyroid remnant 131-I uptake or
with metastatic disease before the therapy7. The stands
about duration of the low iodine diet are not reconciled;
some authors recommend its implementation during 3
weeks5,9, 2 weeks4,6; that is 1–2 weeks3,8 before the 131-I
administration. The Dutch guidelines recommend the
diet implementation 1 week before the hospital admit-
tance and few days during of stay7. Except of low iodine
diet, it is often recommended to avoid iodine contrast
agents, antiseptics, eye drops, amiodarone, multivitamin
and mineral supplements that contain iodine and sea
food 4–6 weeks before the radioiodine therapy6,8. Most of
guidelines recommend the measurement of urine iodine
excretion5,6,9 to exclude iodine excess, especially when
there is doubt8, and, if it is possible, even routinely. In the




The opinions about the postoperative (preablative,
pretherapeutic) 131-I scintigraphy are divided. Some
guidelines indicate its use in almost every patient while
the others recommend it only in certain patients and
even avoiding it if possible. The main reason for avoid-
ance of preablative scintigraphy the authors find in the
»stunning« phenomenon, that is, negative effect of diag-
nostic use of 131-I on later therapy with 131-I30.
The Dutch guidelines recommend the preablative
scintigraphy because of the easier monitoring of all pa-
tients, except those with unifocal carcinoma <1 cm,
without proven metastatic disease7. On the contrary, the
ETA guidelines question the use of diagnostic scinti-
graphy for its little clinical benefit and possible stunning.
In the case of questionable extent of operation procedure
a scintigraphy with 123-I or with low 131-I activities (1
mCi) can be used9. The authors of the BTA guidelines
haven’t found the indication for routine use of preabla-
tive scintigraphy. It can be used for the thyroid remnant
evaluation, but even in that case it is recommended to
use the 123-I or 99mTc-pertechnetate4.
The DGN guidelines recommend the use of 123-I in
the scintigraphy of neck region after the ablation, that is,
the whole body scintigraphy after the radioiodine ther-
apy of metastatic disease. Instead of 123-I, the low activi-
ties (1–10 mCi) of 131-I can also be used6. The recom-
mendation for postoperative scintigraphy according to
the NCCN is marked as the 2B category of recommenda-
tion, which means there is no unique stand about it. In
the decision making the possibility of stunning should be
considered, and in any case it is recommended to reduce
the period between the diagnostic and therapeutic use of
131-I12.
The authors of ATA guidelines state the significance
of preablative scintigraphy in the thyroid remnant size
evaluation, when it is impossible to determine it from ul-
trasound and surgical findings. In the case of indication
for this test the small activities of 131-I (1-3 mCi) are
recommended3. The EANM guidelines do not recom-
mend the use of pretherapeutic scintigraphy when there
is indication for the 131-I therapy. If the scintigraphy is
performed, it is recommended to use 123-I or low activi-
ties 131-I8. In CTS guidelines the preablative scinti-
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graphy is often avoided and it is used only when the re-
sults of scintigraphy are necessary for the decision on
therapy or therapeutic activity of 131-I5.
Conclusion
The indications and procedures for implementing ab-
lation, that is, radioiodine therapy, significantly differ ac-
cording to certain guidelines. The biggest disagreements
exist between the criteria for setting up indications for
use of 131-I and determining the optimal ablative activ-
ity in the low risk group of patients, that is, regarding the
conductance of postoperative 131-I diagnostic scintigra-
phy. The guidelines differ in their shape and the method-
ology for evidence – based recommendations. Most of the
guidelines suggest use of low iodine diet. Also, the suffi-
cient level of TSH is not very different among certain
guidelines. All the guidelines need to be updated with
high level of evidences on a regular basis in order the rec-
ommendations could have higher clinical significance.
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POSTOPERATIVNA PRIMJENA RADIOAKTIVNOG JODA (131-I):
PREGLED SMJERNICA I PREPORUKA
S A @ E T A K
Va`nu ulogu u lije~enju velikog broja bolesnika s diferenciranim karcinomom {titnja~e ~ini primjena radioaktivnog
joda (131-I). U prethodnih nekoliko godina objavljene su i obnovljene smjernice mnogih me|unarodnih i nacionalnih
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lije~ni~kih dru{tava koje se odnose na postoperativnu primjenu 131-I. Smjernice se me|usobno razlikuju u svom obliku
i u sadr`aju te sadr`e neke posebnosti. U smjernicama se koriste razli~iti sustavi vrednovanja i analiziranja ja~ine
klini~kog dokaza i stupnjeva preporuke koje iz toga proizlaze. Postoperativna primjena 131-I ozna~ava radiojodnu abla-
ciju, kao oblik adjuvantnog lije~enja te radiojodnu terapiju u lije~enju bolesnika s recidivom, perzistentnom bolesti te
regionalnim ili udaljenim metastazama. Prema indikaciji za postoperativnu primjenu 131-I bolesnici se mogu podijeliti
u tri rizi~ne skupine: skupinu vrlo niskog rizika u kojoj ne postoji indikacija za postoperativnu primjenu 131-I, skupinu
niskog rizika u kojoj se indikacija mo`e razmotriti te skupinu visokog rizika kod koje postoji jasna indikaciju za prim-
jenu 131-I. U pojedinim smjernicama se navode razli~iti kriteriji za podjelu bolesnika u ove tri skupine. Mi{ljenja se
razlikuju o dozi 131-I potrebnoj za efikasnu ablaciju u skupini bolesnika niskog rizika. Mi{ljenja o provo|enju postope-
rativne (preablacijske odnosno preterapijske) scintigrafije s 131-I su podijeljena. U pripremi bolesnika za radiojodnu
ablaciju i terapiju u svim smjernicama se savjetuje primjena dijete s malo joda te endogena ili egzogena stimulacija
TSH. Endogena stimulacija se posti`e povla~enjem hormona {titnja~e, dok se rekombinantni humani TSH (rhTSH)
koristi u egzogenoj stimulaciji. Dostatna razina TSH u serumu potrebna za provo|enje terapije s 131-I iznosi >25–30
mU/L.
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